Summary
EudraCT Number: 2007-007758-70
Sponsor's Protocol Code Number: NH19707
National Competent Authority: Hungary - National Institute of Pharmacy 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2008-07-01
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-007758-70/HU/

A. Protocol Information
A.1 Member State Concerned: Hungary - National Institute of Pharmacy
A.2 EudraCT number: 2007-007758-70
A.3 Full title of the trial: An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA® for maintenance treatment of anemia in pediatric patients with chronic kidney disease on hemodialysis.

A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language: A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis. 
A.3.2 Name or abbreviated title of the trial where available: DOLPHIN
A.4.1 Sponsor's protocol code number: NH19707
A.5.2 US NCT (ClinicalTrials.gov registry) number: NCT00717366
A.7 Trial is part of a Paediatric Investigation Plan: Yes
A.8 EMA Decision number of Paediatric Investigation Plan: P/26/2009

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: F. Hoffmann-La Roche Ltd
B.1.3.4	Country: Switzerland
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support: F. Hoffmann-La Roche Ltd
B.4.2 Country: Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: F. Hoffmann-La Roche Ltd
B.5.2 Functional name of contact point: Trial Information Support Line-TISL
B.5.3 Address
B.5.3.1 Street Address: Grenzacherstrasse 124
B.5.3.2 Town/ city: Basel
B.5.3.3 Post code: 4070
B.5.3.4 Country: Switzerland
B.5.6 E-mail: global.rochegenentechtrials@roche.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 30/0.3 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 50/0.3 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 3
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 75/0.3 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 4
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 120/0.3 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 5
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 200/0.3 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 6
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: MIRCERA®
D.2.1.1.2 Name of the Marketing Authorisation holder: Roche Registration Limited
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Solution for injection
D.3.4.1 Specific paediatric formulation: No
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: methoxy polyethylene glycol-epoetin beta
D.3.9.1 CAS number: 677324-53-7
D.3.9.2 Current sponsor code: RO0503821
D.3.10 Strength
D.3.10.1 Concentration unit: µg/ml microgram(s)/millilitre
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 360/0.6 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: No
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes
D.3.11.3 Advanced Therapy IMP (ATIMP): No
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: No
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): No
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: No
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: No
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Yes
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Anemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysis 
E.1.1.1 Medical condition in easily understood language: Anemia
E.1.1.2 Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 17.0
E.1.2 Level: LLT
E.1.2 Classification code: 10058124
E.1.2 Term: Nephrogenic anemia
E.1.2 System Organ Class: 100000004851
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: - To determine the starting dose of MIRCERA® in pediatric patients with CKD on hemodialysis when switching from stable maintenance treatment with epoetin alfa, epoetin beta or darbepoetin alfa
- To demonstrate changes in Hb over time in response to different iv doses of MIRCERA®
E.2.2 Secondary objectives of the trial: - To study the pharmacokinetics (PK) of MIRCERA® in pediatric patients
- To explore MIRCERA® exposure response relationship
- To assess the safety and tolerability of multiple doses of MIRCERA® in pediatric patients
- To document long-term safety and efficacy of MIRCERA® administration in pediatric patients with anemia associated with CKD
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria:  - written informed consent from parent/legal guardian and/or assent from child where appropriate as required by national legislation

  - children aged 5-17 years (in Russia only: 12-17 years) with clinically stable chronic renal anemia;

  - hemodialysis for >=8 weeks;

  - intravenous stable maintenance epoetin alfa, epoetin beta or darbepoetin alfa for >= 8 weeks before screening and with no weekly dose change >/=25% (increase or decrease) during the 2 weeks of screening.
E.4 Principal exclusion criteria:   - overt gastrointestinal bleeding, or bleeding episode necessitating transfusion within 8 weeks before screening;

  - red blood cell (RBC) transfusions within 8 weeks before screening;

  - active malignant disease;

  - pure red cell aplasia (PRCA) or history of PRCA;

  - pregnant or lactating;

  - for sexually active patients: not willing to use reliable contraception.
E.5 End points
E.5.1 Primary end point(s): - Change in Hb concentration between baseline and evaluation period.
E.5.1.1 Timepoint(s) of evaluation of this end point: Weeks 17-20
E.5.2 Secondary end point(s): 1. Incidence of RBC transfusions, reticulocyte counts, adverse events, laboratory parameters.

2. Number of patients with average Hb concentration above, below or within range of 10-12g/dL during evaluation period.
E.5.2.1 Timepoint(s) of evaluation of this end point: 1. Throughout study, up to 1 year

2. Weeks 17-20  

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Yes
E.6.8 Bioequivalence: No
E.6.9 Dose response: Yes
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: Information not present in EudraCT
E.8.1.2 Open: Information not present in EudraCT
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Information not present in EudraCT
E.8.2.2 Placebo: Information not present in EudraCT
E.8.2.3 Other: Information not present in EudraCT
E.8.2.4 Number of treatment arms in the trial: 2
E.8.3 The trial involves single site in the Member State concerned: Yes
E.8.4 The trial involves multiple sites in the Member State concerned: No
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 10
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: No
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
Australia
Belgium
France
Germany
Hungary
Italy
Poland
Romania
Russian Federation
Spain
Thailand
Ukraine
E.8.7 Trial has a data monitoring committee: Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: The end of this study is defined as the end of Week 21 after the last patient has been recruited. The study protocol offers, however, an optional safety extension phase. For patients participating on this safety extension phase, the study will end 73 weeks after the last patient has been recruited.
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 8
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 8
E.8.9.2 In all countries concerned by the trial months: 0
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: Yes
F.1.1 Number of subjects for this age range: 68
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): Yes
F.1.1.5.1 Number of subjects for this age range: 22
F.1.1.6 Adolescents (12-17 years): Yes
F.1.1.6.1 Number of subjects for this age range: 46
F.1.2 Adults (18-64 years): No
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: No
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: Yes
F.3.3.6.1 Details of subjects incapable of giving consent: Paediatric Population
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 5
F.4.2 For a multinational trial
F.4.2.2 In the whole clinical trial: 68
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): 'None'.

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2008-10-18
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2008-10-08

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2016-03-29

